https://www.taxtmi.com/news?id=60081 Supraflex Cruz is reported across randomized trials, an elderly cohort study, and a large registry to demonstrate consistent safety and efficacy, with randomized comparisons (TUXEDO II and Multivessel TALENT) supporting non-inferiority on primary endpoints including Target Lesion Failure, and real world registry data and senior patient outcomes corroborating procedural success and low rates of clinically driven revascularization. en-us Wed, 29 Oct 2025 17:31:03 +0530 Wed, 29 Oct 2025 17:31:04 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=60081 Supraflex Cruz is reported across randomized trials, an elderly cohort study, and a large registry to demonstrate consistent safety and efficacy, with randomized comparisons (TUXEDO II and Multivessel TALENT) supporting non-inferiority on primary endpoints including Target Lesion Failure, and real world registry data and senior patient outcomes corroborating procedural success and low rates of clinically driven revascularization. News - Wed, 29 Oct 2025 17:31:03 +0530 https://www.taxtmi.com/news?id=60081